Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Characterization of a sensitive mouse Aβ40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice.

Lu Y, Hoyte K, Montgomery WH, Luk W, He D, Meilandt WJ, Zuchero YJ, Atwal JK, Scearce-Levie K, Watts RJ, DeForge LE.

Bioanalysis. 2016 May;8(10):1067-75. doi: 10.4155/bio-2016-0003. Epub 2016 Apr 20.

PMID:
27094761
2.

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.

Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA, Scearce-Levie K, Couch JA, Dennis MS, Watts RJ.

Sci Transl Med. 2014 Nov 5;6(261):261ra154. doi: 10.1126/scitranslmed.3009835.

3.
4.

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.

May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE.

J Neurosci. 2011 Nov 16;31(46):16507-16. doi: 10.1523/JNEUROSCI.3647-11.2011.

5.

Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG.

J Neurosci. 2001 Jan 15;21(2):372-81.

7.

7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease.

Devi L, Ohno M.

Neuropsychopharmacology. 2012 Jan;37(2):434-44. doi: 10.1038/npp.2011.191. Epub 2011 Sep 7.

8.

Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease.

Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X, Cook JJ, Simon AJ, Savage MJ.

J Neurosci Res. 2012 Dec;90(12):2247-58. doi: 10.1002/jnr.23122. Epub 2012 Sep 18.

PMID:
22987781
9.

Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model.

Durairajan SS, Liu LF, Lu JH, Chen LL, Yuan Q, Chung SK, Huang L, Li XS, Huang JD, Li M.

Neurobiol Aging. 2012 Dec;33(12):2903-19. doi: 10.1016/j.neurobiolaging.2012.02.016. Epub 2012 Mar 27.

PMID:
22459600
10.

Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.

Georgievska B, Gustavsson S, Lundkvist J, Neelissen J, Eketjäll S, Ramberg V, Bueters T, Agerman K, Juréus A, Svensson S, Berg S, Fälting J, Lendahl U.

J Neurochem. 2015 Feb;132(4):477-86. doi: 10.1111/jnc.12937. Epub 2014 Sep 18.

11.

Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice.

Arbel-Ornath M, Becker M, Rabinovich-Toidman P, Gartner M, Solomon B.

J Alzheimers Dis. 2010;22(2):469-82. doi: 10.3233/JAD-2010-100753.

PMID:
20847413
12.

P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.

Meredith JE Jr, Thompson LA, Toyn JH, Marcin L, Barten DM, Marcinkeviciene J, Kopcho L, Kim Y, Lin A, Guss V, Burton C, Iben L, Polson C, Cantone J, Ford M, Drexler D, Fiedler T, Lentz KA, Grace JE Jr, Kolb J, Corsa J, Pierdomenico M, Jones K, Olson RE, Macor JE, Albright CF.

J Pharmacol Exp Ther. 2008 Aug;326(2):502-13. doi: 10.1124/jpet.108.138974. Epub 2008 May 22.

PMID:
18499745
13.

Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.

Zhou QH, Fu A, Boado RJ, Hui EK, Lu JZ, Pardridge WM.

Mol Pharm. 2011 Feb 7;8(1):280-5. doi: 10.1021/mp1003515. Epub 2010 Dec 21.

14.

Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.

Mao P, Manczak M, Calkins MJ, Truong Q, Reddy TP, Reddy AP, Shirendeb U, Lo HH, Rabinovitch PS, Reddy PH.

Hum Mol Genet. 2012 Jul 1;21(13):2973-90. doi: 10.1093/hmg/dds128. Epub 2012 Apr 5.

15.

Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.

Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF.

Eur J Neurosci. 2006 Jan;23(1):251-60.

PMID:
16420434
16.

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E.

J Neurosci Res. 2006 May 15;83(7):1252-61.

PMID:
16511867
17.

Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.

Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ.

J Neurosci Res. 2011 Jun;89(6):822-32. doi: 10.1002/jnr.22618. Epub 2011 Mar 23.

PMID:
21433051
18.

Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.

Dorresteijn B, Rotman M, Faber D, Schravesande R, Suidgeest E, van der Weerd L, van der Maarel SM, Verrips CT, El Khattabi M.

FEBS J. 2015 Sep;282(18):3618-31. doi: 10.1111/febs.13367. Epub 2015 Jul 22.

19.

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.

Neumann U, Rueeger H, Machauer R, Veenstra SJ, Lueoend RM, Tintelnot-Blomley M, Laue G, Beltz K, Vogg B, Schmid P, Frieauff W, Shimshek DR, Staufenbiel M, Jacobson LH.

Mol Neurodegener. 2015 Sep 3;10:44. doi: 10.1186/s13024-015-0033-8.

20.

AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.

Eketjäll S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, Gustavsson S, Radesäter AC, Eliason K, Briem S, Appelkvist P, Niva C, Berg AL, Karlström S, Swahn BM, Fälting J.

J Neurosci. 2013 Jun 12;33(24):10075-84. doi: 10.1523/JNEUROSCI.1165-13.2013.

Supplemental Content

Support Center